Navigation Links
ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies
Date:6/8/2011

MENLO PARK, Calif., June 8, 2011 /PRNewswire/ -- ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Anti-Mouse IgG Fc Capture (AMC) biosensor for use on the company's Octet® instrumentation platform. The new biosensor enables high-throughput rapid kinetic characterization and screening of mouse antibodies and other Fc-containing proteins with unprecedented ease of use and cost efficiency.

"With the introduction of our new AMC biosensor, researchers can now benefit from ForteBio's off-the-shelf, label-free biosensors during discovery projects using murine models, as well as when working with human antibodies," said Christopher Silva, ForteBio's vice president of marketing, noting that the company already offers its Anti-Human IgG Fc Capture (AHC) biosensor for analysis of human IgG antibodies. "Our AMC biosensor eliminates the need for inconvenient, labor-intensive steps typically associated with ELISA and SPR methods for screening and kinetic characterization, and thereby facilitates high-throughput research applications such as hybridoma screening and characterization."

The new AMC biosensor enables immobilization of mouse Fc-containing proteins upon the biosensor directly, from a crude or purified matrix, without the need to biotinylate. Additionally, AMC biosensors can be regenerated and reused up to 10 times.

"Our new AMC biosensor can also work fluidly with ForteBio's other research tools for increased speed, ease of use and cost efficiency," said Mr. Silva. "For example, researchers using our Protein G biosensor to titer hybridoma samples can now use our AMC biosensor to perform kinetics and affinity analysis on resulting epitopes of interest – all from the same crude sample."

ForteBio's Anti-Human IgG Fc Capture biosensor is ready to use on the company's Octet instruments. ForteBio's Octet platform is based on the company's proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterization and quantitation by eliminating throughput and time-to-result limitations of traditional SPR-based assays and ELISA. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

ABOUT FORTEBIO, INC.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.


'/>"/>
SOURCE ForteBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
2. ForteBio Announces Launch of Protein G Biosensor for Use on Companys Octet® Instruments
3. ForteBio Launches New Octet® RED96 System and Dip and Read™ Protein L Biosensor
4. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
5. Dr. Dello Russo Introduces the New EYE-Q Lasik
6. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
7. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
8. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
9. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
10. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
11. Siemens Introduces New Standard of Care for Breast Ultrasound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
Breaking Medicine News(10 mins):